Dialysis of Little Benefit to Elderly End-Stage Renal Disease Patients

This article originally appeared here.
Share this content:
Dialysis of Little Benefit to Elderly End-Stage Renal Disease Patients
Dialysis of Little Benefit to Elderly End-Stage Renal Disease Patients

FRIDAY, March 18, 2016 (HealthDay News) -- Dialysis does not significantly improve survival for elderly patients with end-stage renal disease (ESRD), according to research published online March 17 in the Clinical Journal of the American Society of Nephrology.

Wouter Verberne, M.D., of St. Antonius Hospital in Nieuwegein, Netherlands, and colleagues examined outcomes among older (≥70 years) ESRD patients in the Netherlands who received either dialysis (204 patients) or conservative care (107 patients).

Overall, patients with comorbidities died sooner than those without additional medical issues, the study authors reported. Among those ≥80 years of age, the investigators found no statistically significant difference in survival between dialysis and conservative care. The findings suggest that conservative care may be a reasonable option for some ESRD patients ≥80.

"We do not conclude that dialysis treatment should not be given to anybody ≥80 years or with severe comorbidity. But we show that the treatment is on average of little advantage regarding survival," Verberne said in a journal news release. "Our next task is to predict who benefits and who does not. Until we are able to give a better prediction of the results of dialysis treatment at high age, we can merely suggest that conservative management is an option which should honestly be discussed when ESRD is approaching."

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths